"AbbVie reported Q1 2026 revenue of $15 billion, beating the $14.72 billion consensus and growing 12.43% YoY. Adjusted EPS of $2.65 missed by $0.02, but a $744 million IPR&D charge clipped $0.41 per share."
"Skyrizi grew 30.9% YoY to $4.48 billion, Rinvoq grew 23.3% to $2.12 billion, and the migraine franchise is on fire with Qulipta +53.6%, Ubrelvy +41.4%."
"The bull-case scenario reaches $253.25, a 24.21% total return, supported by AbbVie's successful post-Humira pivot and strong pipeline candidates."
AbbVie reported Q1 revenue of $15 billion, exceeding expectations and growing 12.43% year-over-year. Despite a slight miss in adjusted EPS, management raised full-year guidance. Skyrizi and Rinvoq demonstrated significant growth, contributing to a positive outlook. The stock is rated a buy with a price target of $229.32, indicating potential upside. Risks include declining sales of Humira and Imbruvica, alongside a notable GAAP net income drop. The overall market sentiment remains bullish with a consensus target of $249.27.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]